<< Back to News

NEJM Article on KEYTRUDA® (pembrolizumab)

Merck is pleased to share an April 2018 New England Journal of Medicine publication that discusses KEYTRUDA® (pembrolizumab) plus chemotherapy in metastatic non-small-cell lung cancer.

Please click the link below to access the journal article. Please click the link below to access the journal article. 

CLICK HERE TO ACCESS THE PUBLICATION